EHA23 Insights into the Changing Landscape of Myeloma Treatments

In his MEDtalk from EHA23, Fredrik Schjesvold, leader of the Oslo Myeloma Center, Oslo University Hospital, discusses the dynamic changes in the landscape of myeloma treatments. Additionally, Fredrik nuances the recent data on the BCMA antibody belantamab mafodotin, highlighting its advantages in terms of response duration and depth, making it a valuable option for late-line treatment.